Immunoglobulin Y(Ig Y)is an effective orally administered antibody used to protect against various intestinal pathogens,but which cannot tolerate the acidic gastric environment.In this study,Ig Y was microencapsulated...Immunoglobulin Y(Ig Y)is an effective orally administered antibody used to protect against various intestinal pathogens,but which cannot tolerate the acidic gastric environment.In this study,Ig Y was microencapsulated by alginate(ALG)and coated with chitooligosaccharide(COS).A response surface methodology was used to optimize the formulation,and a simulated gastrointestinal(GI)digestion(SGID)system to evaluate the controlled release of microencapsulated Ig Y.The microcapsule formulation was optimized as an ALG concentration of 1.56%(15.6 g/L),COS level of 0.61%(6.1 g/L),and Ig Y/ALG ratio of 62.44%(mass ratio).The microcapsules prepared following this formulation had an encapsulation efficiency of 65.19%,a loading capacity of 33.75%,and an average particle size of 588.75μm.Under this optimum formulation,the coating of COS provided a less porous and more continuous microstructure by filling the cracks on the surface,and thus the GI release rate of encapsulated Ig Y was significantly reduced.The release of encapsulated Ig Y during simulated gastric and intestinal digestion well fitted the zero-order and first-order kinetics functions,respectively.The microcapsule also allowed the Ig Y to retain 84.37%immune-activity after 4 h simulated GI digestion,significantly higher than that for unprotected Ig Y(5.33%).This approach could provide an efficient way to preserve Ig Y and improve its performance in the GI tract.展开更多
基金Project supported by the National Key Research and Development Program of China(No.2018YFD0400305)the Modern Agro-industry Technology Research System of China(No.CARS-40-K26)the“One Belt and One Road”International Science and Technology Cooperation Program of Zhejiang,China(No.2019C04022)。
文摘Immunoglobulin Y(Ig Y)is an effective orally administered antibody used to protect against various intestinal pathogens,but which cannot tolerate the acidic gastric environment.In this study,Ig Y was microencapsulated by alginate(ALG)and coated with chitooligosaccharide(COS).A response surface methodology was used to optimize the formulation,and a simulated gastrointestinal(GI)digestion(SGID)system to evaluate the controlled release of microencapsulated Ig Y.The microcapsule formulation was optimized as an ALG concentration of 1.56%(15.6 g/L),COS level of 0.61%(6.1 g/L),and Ig Y/ALG ratio of 62.44%(mass ratio).The microcapsules prepared following this formulation had an encapsulation efficiency of 65.19%,a loading capacity of 33.75%,and an average particle size of 588.75μm.Under this optimum formulation,the coating of COS provided a less porous and more continuous microstructure by filling the cracks on the surface,and thus the GI release rate of encapsulated Ig Y was significantly reduced.The release of encapsulated Ig Y during simulated gastric and intestinal digestion well fitted the zero-order and first-order kinetics functions,respectively.The microcapsule also allowed the Ig Y to retain 84.37%immune-activity after 4 h simulated GI digestion,significantly higher than that for unprotected Ig Y(5.33%).This approach could provide an efficient way to preserve Ig Y and improve its performance in the GI tract.
